Canurta Advances ALS Research and Healthspan Innovation on the Global Stage

34th International Symposium on ALS/MND in Basel, Switzerland

CEO Akeem Gardner's recent participation in the 34th International Symposium on ALS/MND in Basel marked a profoundly memorable experience.

Over three days, he engaged in enlightening discussions and updates on groundbreaking research, clinical trials, and patient care within the ALS/MND field. Interacting with dedicated experts and patient advocates was a significant highlight, emphasizing the real impact of Canurta's mission.

We eagerly anticipate contributing to the 35th Symposium in Montreal next December, further reinforcing our commitment to the fight against ALS/MND through collaboration and progress.

Canurta CEO's Insights from the Hevolution Foundation's Inaugural Global Healthspan Summit in Riyadh, Saudi Arabia

Reflecting on key takeaways from the Hevolution Foundation Global Healthspan Summit in Riyadh. For our CEO the event was both inspiring and energizing, reinforcing our commitment to advancing botanical therapeutics at Canurta.

The summit emphasized the need for a paradigm shift in our industry, from disease treatment to healthy living and extending Healthspan.

This summit marked a pivotal moment, validating our path and fueling our determination to shape the future. We've built valuable relationships and are ready for what lies ahead.

Canurta Selected to Present at OBIO Investment Summit Feb 14-16

Canurta is proud to be selected to present at the Ontario Bioscience Innovation Organization (OBIO) Investment Summit that has raised more than $1.6B for participating companies since 2018.

The focus is on health science companies commercializing products and services in therapeutics, medical devices, diagnostics, digital health and health IT.

Learn More

Canurta's November Milestones

Operations

Seamless Transition to Microsoft Platforms: We have smoothly transitioned to Microsoft platforms, enhancing our operational efficiency.

Establishing Clinical Operations: We are actively laying the groundwork for vendor selection and planning clinical trials for the upcoming year.

Research & Development

ALS Formulation Progress: Toxicity trials have been wrapped up for the ALS formulation in the zebrafish model and initiated efficacy assays.

Bioinformatics

Vital ALS Biomarkers: We've pinpointed essential inflammation biomarkers for ALS and are currently validating them through meticulous data analysis.

Innovative Screening Process: We're transforming our natural product screening with a cutting-edge graph neural network.